GlassScriptPhysician profile
Shounak Das
NPI 1376710095
$2,806.31
in general payments reported to CMS, 2019-2025
27 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $307 · 2021: $209 · 2022: $359 · 2023: $234 · 2024: $463 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,078.02 | 2019-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $245.33 | 2019-2021 | |
| Pfizer INC. | $176.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $141.13 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $139.76 | 2023-2025 | Mounjaro, Zepbound |
| Sanofi Pasteur INC. | $129.35 | 2019-2020 | |
| Astellas Pharma US INC | $94.68 | 2019 | |
| Novo Nordisk INC | $90.88 | 2021-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $85.14 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $69.80 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $69.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.84 | 2022-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $67.05 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $41.95 | 2024 | Intellis Adaptivestim |
| Dynavax Technologies Corporation | $40.64 | 2023-2024 | Heplisav-B |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38.63 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $34.79 | 2024 | Ultomiris |
| Insmed, INC. | $30.22 | 2025 | Arikayce |
| Boston Scientific Corporation | $29.79 | 2025 | Watchman Flx |
| Inari Medical, INC. | $27.13 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $16.73 | 2022 | |
| Curonix LLC | $16.55 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Gilead Sciences, INC. | $16.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.25 | 2019 | |
| Opko Pharmaceuticals, LLC | $14.84 | 2024 | Rayaldee |
| Vertex Pharmaceuticals Incorporated | $14.61 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shounak Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.